Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jia...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212116/full |
| _version_ | 1797673998202437632 |
|---|---|
| author | Rui Luo Rui Luo Rui Luo Chongkai Fang Chongkai Fang Chongkai Fang Chongkai Fang Chuyao Chen Chuyao Chen Chuyao Chen Ying Zhang Ying Zhang Ying Zhang Ruiwei Yao Ruiwei Yao Ruiwei Yao Jinan Wang Jinan Wang Jinan Wang Hanqian Shi Hanqian Shi Hanqian Shi Kunliang Feng Mingli Hu Chong Zhong Chong Zhong Chong Zhong |
| author_facet | Rui Luo Rui Luo Rui Luo Chongkai Fang Chongkai Fang Chongkai Fang Chongkai Fang Chuyao Chen Chuyao Chen Chuyao Chen Ying Zhang Ying Zhang Ying Zhang Ruiwei Yao Ruiwei Yao Ruiwei Yao Jinan Wang Jinan Wang Jinan Wang Hanqian Shi Hanqian Shi Hanqian Shi Kunliang Feng Mingli Hu Chong Zhong Chong Zhong Chong Zhong |
| author_sort | Rui Luo |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC. |
| first_indexed | 2024-03-11T21:53:50Z |
| format | Article |
| id | doaj.art-838a5d5d77ef48ce880ad6308ab85f17 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T21:53:50Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-838a5d5d77ef48ce880ad6308ab85f172023-09-26T06:41:46ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-09-011410.3389/fphar.2023.12121161212116Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching studyRui Luo0Rui Luo1Rui Luo2Chongkai Fang3Chongkai Fang4Chongkai Fang5Chongkai Fang6Chuyao Chen7Chuyao Chen8Chuyao Chen9Ying Zhang10Ying Zhang11Ying Zhang12Ruiwei Yao13Ruiwei Yao14Ruiwei Yao15Jinan Wang16Jinan Wang17Jinan Wang18Hanqian Shi19Hanqian Shi20Hanqian Shi21Kunliang Feng22Mingli Hu23Chong Zhong24Chong Zhong25Chong Zhong26The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Surgery, Baiyun Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe Second Affiliated Hospital of Guizhou University of Chinese Medicine, Guizhou, ChinaThe First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, ChinaHepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC.https://www.frontiersin.org/articles/10.3389/fphar.2023.1212116/fullhepatocellular carcinomahepatectomytumor recurrencetraditional Chinese medicineadjuvant therapy |
| spellingShingle | Rui Luo Rui Luo Rui Luo Chongkai Fang Chongkai Fang Chongkai Fang Chongkai Fang Chuyao Chen Chuyao Chen Chuyao Chen Ying Zhang Ying Zhang Ying Zhang Ruiwei Yao Ruiwei Yao Ruiwei Yao Jinan Wang Jinan Wang Jinan Wang Hanqian Shi Hanqian Shi Hanqian Shi Kunliang Feng Mingli Hu Chong Zhong Chong Zhong Chong Zhong Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study Frontiers in Pharmacology hepatocellular carcinoma hepatectomy tumor recurrence traditional Chinese medicine adjuvant therapy |
| title | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
| title_full | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
| title_fullStr | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
| title_full_unstemmed | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
| title_short | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
| title_sort | adjuvant therapy with jianpi huayu decoction improves overall and recurrence free survival after hepatectomy for hepatocellular carcinoma a retrospective propensity score matching study |
| topic | hepatocellular carcinoma hepatectomy tumor recurrence traditional Chinese medicine adjuvant therapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212116/full |
| work_keys_str_mv | AT ruiluo adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT ruiluo adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT ruiluo adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongkaifang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongkaifang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongkaifang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongkaifang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chuyaochen adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chuyaochen adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chuyaochen adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT yingzhang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT yingzhang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT yingzhang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT ruiweiyao adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT ruiweiyao adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT ruiweiyao adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT jinanwang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT jinanwang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT jinanwang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT hanqianshi adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT hanqianshi adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT hanqianshi adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT kunliangfeng adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT minglihu adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongzhong adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongzhong adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chongzhong adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy |